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Background: Ibuprofen is known to be efficacious in the treatment of tension-type headache, the most common
form of primary headache. A novel tablet formulation of ibuprofen sodium is more rapidly absorbed than standard
ibuprofen. This study evaluated onset of analgesia and overall efficacy of ibuprofen sodium in episodic-type tension
headache (ETTH) compared with standard ibuprofen and placebo.
Methods: This randomized, double-blind, single-center, parallel-group study included adults aged 18–65 years
with ≥4 moderately severe ETTHs per month for 6 months. Within 45 minutes of onset of at least moderately
severe ETTH, subjects were randomized 2:2:1 to receive a single oral dose of ibuprofen sodium tablets (Advil® Film
Coated; 2 × 256 mg [equivalent to 400 mg standard ibuprofen]), standard ibuprofen tablets (Motrin®; 2 × 200 mg),
or placebo. The coprimary end points were time-weighted sum of pain relief rating and pain intensity difference
scores over 3 hours (SPRID 0–3) and time to meaningful pain relief (MPR) assessed by double-stopwatch method.
Results: A total of 226 subjects were randomized to ibuprofen sodium (n = 91), standard ibuprofen (n = 89), and
placebo (n = 46). Demographics and baseline characteristics were comparable between treatment groups. Mean
SPRID 0–3 scores were significantly superior (P < .001) for ibuprofen sodium (9.6) and standard ibuprofen (9.8) versus
placebo (3.5), but were not significantly different from each other (P = .812). Time to MPR was significantly (P < .001)
shorter for ibuprofen sodium and standard ibuprofen compared with placebo (median 40.6, 48.5, and >180 minutes,
respectively). Time to MPR was numerically faster for ibuprofen sodium than standard ibuprofen. This difference was
not statistically significant (P = .253) using the protocol-specified analysis but was (P = .022) in a post hoc analysis using
the Gehan-Wilcoxon test, which assigns higher weights to earlier events. (The post hoc analysis was performed because
Kaplan-Meier graphs and results for time to first perceptible relief favored ibuprofen sodium over standard ibuprofen at
earlier time points.) There were no adverse events.
Conclusions: This novel ibuprofen sodium tablet provided rapid, efficacious relief of ETTH and was well tolerated.
Trial registration: ClinicalTrials.gov NCT01362491.
Keywords: Ibuprofen sodium, Fast-absorbed ibuprofen, Tension headache, Analgesia, Over the counterBackground
Tension-type headache is the most common type of pri-
mary headache, with a lifetime prevalence in the general
population ranging from 30% to 78% [1]. Diagnostic cri-
teria for episodic tension-type headache (ETTH), as per
The International Classification of Headache Disorders,
2nd edition, include having at least 10 headache episodes
(lasting 30 minutes to 7 days) occurring on fewer than
15 days per month over a period of at least 3 months* Correspondence: David.Kellstein@pfizer.com
2Pfizer Consumer Healthcare, 1 Giralda Farms, Madison, NJ 07940, USA
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unless otherwise stated.[1]. Additionally, at least 2 of the following items must
be present for a diagnosis of ETTH: bilateral location, a
feeling of pressure or tightening, mild or moderate in-
tensity, and lack of exacerbation by routine physical ac-
tivity [1].
Ibuprofen (IBU) is a nonsteroidal anti-inflammatory
drug (NSAID) that is widely available without a prescrip-
tion (i.e., over the counter [OTC]) for the relief of acute
pain resulting from various causes, including headache
[2]. In many countries, nonprescription IBU labeling dic-
tates using a maximum single dose of 400 mg, which
can be administered up to 3 times per day as needed.al. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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the efficacy of OTC IBU in the treatment of tension-
type headache [3], dental pain [4,5], sore throat [6], and
postpartum episiotomy pain [7].
When acute pain necessitates a pharmacologic inter-
vention, pain sufferers desire relief as quickly as possible.
Serum concentrations of IBU are highly correlated with
the level of analgesia [8]. Pharmacologic enhancements
increasing IBU solubility in water facilitate gastric and
enteric mucosal absorption, potentially leading to a faster
onset of pain relief [9]. Considerable efforts have been
expended to develop faster-absorbed formulations of IBU
for that purpose. These efforts include the development of
soft gelatin capsules containing solubilized IBU [10] and
salt forms of IBU, e.g., arginine [9,11], lysine [10], and so-
dium [12] salts. Several studies have confirmed that IBU
salt formulations provide a clinical advantage of more
rapid pain relief in comparison to standard IBU in subjects
with postsurgical dental pain [9,11,13-15].
Most recently, a novel immediate-release tablet con-
taining 256 mg of IBU sodium dihydrate (IBUNa; equiva-
lent to 200 mg of IBU free acid) has been developed.
Pharmacokinetic studies have demonstrated that this
formulation of IBUNa is absorbed faster than standard
IBU tablets, and as fast as both solubilized IBU and IBU
lysine [16]. In a clinical study of postsurgical dental pain,
the pharmacokinetic advantage of IBUNa tablets was
translated into more rapid pain relief than that achieved
with standard IBU tablets [17]. In order to gain further
insight into the efficacy of IBUNa in an additional pain
state, the current study (NCT01362491) evaluated the
onset, and overall analgesic efficacy, of a single oral dose
of IBUNa tablets in comparison with standard IBU and
placebo in the treatment of ETTH when both active
treatments were administered at a dose that was equiva-
lent to 400 mg of IBU acid. Our hypothesis was that
IBUNa would provide a faster onset of analgesia com-
pared with standard IBU tablets and have superior over-
all analgesic efficacy compared with placebo.
Methods
Subjects and study design
This single-center, randomized, double-blind (third-party
blind), 3-hour, single-dose, placebo-controlled, parallel-
group study was conducted from June 21, 2011, through
March 9, 2012. Healthy men and women (aged 18 to
65 years) who had a diagnosis of ETTH as defined by
the International Headache Society [1] were enrolled.
The headaches had to have begun prior to age 50, be of
at least moderate severity, have a frequency of ≥4 head-
ache episodes per month for 6 months, typically respond
to OTC analgesics, and to last for ≥3 hours if left un-
treated. Women could not be pregnant or lactating and
a medically approved method of contraception wasrequired for women who were premenopausal or had
been postmenopausal for less than 2 years. Subjects were
excluded if the Investigator determined that the presence
or history of a significant medical condition increased
the risk for that subject; if there was a presence or his-
tory of alcohol abuse (≥3 drinks per day on a regular
basis), gastrointestinal bleeding or ulcer, bleeding dis-
order, or substance abuse within the past 2 years; and/or
if there was treatment for depression within the past
6 months. Having a history of recurrent migraine head-
ache (defined as, on average, ≥1 migraine headache per
month over the past 6 months), menstrual headaches, or
habituation to analgesic medications (i.e., routine use of
oral analgesics ≥5 times per week) were also exclusion-
ary. Potential subjects were ineligible if they had taken
any type of analgesic, antipyretic, sedative, or vasoactive
agent within 12 hours of study drug administration, or if
they had ingested any caffeine-containing beverages,
chocolate, or alcohol within 4 hours of study drug. Sub-
jects with a hypersensitivity to any OTC NSAID or acet-
aminophen or who were taking concomitant medication
contraindicated with an NSAID were ineligible.
Subjects meeting the eligibility requirements were
instructed to present to a single clinical research center (In-
stitute for Applied Pharmaceutical Research, Philadelphia,
PA), within 45 minutes of onset of an ETTH. Present-
ing subjects were screened for baseline pain severity
using a 4-Point Categorical Pain Severity Rating (PSR)
Scale (0 = none, 1 = mild, 2 = moderately severe, 3 = se-
vere) and a 100-mm visual analog pain scale (VAS).
Subjects with at least moderately severe baseline head-
ache pain, defined as a score ≥2 on the categorical PSR
and confirmed by score ≥66 mm on the VAS, were eli-
gible for randomization. All subjects provided written
informed consent prior to screening and enrollment.
The study was approved by the Sterling Institutional Re-
view Board (Atlanta, GA) and was conducted in accord-
ance with International Conference on Harmonization
Good Clinical Practice Guidelines and the guiding princi-
ples of the Declaration of Helsinki and amendments
thereof.
Treatment interventions and administration
Subjects were stratified by baseline pain (moderately se-
vere or severe) and gender and randomized in a ratio of
2:2:1 according to a computer-generated randomization
schedule (supplied by Pfizer Consumer Healthcare Bio-
statistics Department, Madison, NJ) to receive a single
oral dose of IBU sodium dihydrate (new Advil® Film-
Coated Tablets [IBUNa]; 2 × 256 mg; equivalent to
400 mg standard IBU; Pfizer Consumer Healthcare),
standard IBU tablets (Motrin® IB [IBUMot]; 2 × 200 mg;
McNeil Consumer Healthcare, Fort Washington, PA), or
placebo (2 tablets). Study drug was administered with 8
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have an identical appearance, subjects were blindfolded
during treatment administration. Aside from a disinter-
ested third party who retained sole possession of the
randomization codes and administered the treatments, all
study personnel and subjects were blinded to the identity
of the study drug. Efficacy was evaluated for 3 hours post-
dose. Rescue medication, at the Investigator’s discretion,
was permitted for subjects not experiencing adequate pain
relief within 2 hours of study treatment administration;
any subjects requiring rescue medication prior to 2 hours
were discontinued from the study.
Efficacy and safety assessments
The double-stopwatch method was used to evaluate time
to first perceptible pain relief (FPR) and time to mean-
ingful pain relief (MPR). The double-stopwatch method
is the FDA-preferred method for assessing onset of anal-
gesia [18] and has been employed extensively in trials of
headache, dental pain, and other pain models [17,19-23].
At the time of treatment administration, the study co-
ordinator or designee started 2 blinded stopwatches. The
subject was given the first stopwatch and told to stop it
as soon as any headache relief was experienced. Once
the subject stopped the first stopwatch, the elapsed time
was recorded as time to FPR and the subject was asked
whether their relief was “meaningful.” If the subject an-
swered affirmatively, then the time to FPR was also con-
sidered the time to MPR. However, if the subject did not
consider the FPR to be meaningful, he/she was given the
second stopwatch and asked to stop it when “meaningful
relief” was achieved; in this scenario, elapsed time on the
second stopwatch was recorded as time to MPR.
At 1, 2, and 3 hours postdose or at the time of rescue
medication use (if applicable), subjects were asked to
rate their pain severity on the 4-point PSR and their pain
relief on a 5-point Categorical Pain Relief Rating (PRR)
Scale (0 = no relief, 1 = a little relief, 2 = some relief, 3 = a
lot of relief, 4 = complete relief ).
Safety was monitored throughout the study. All adverse
events (AEs), observed or volunteered, were to be re-
corded using Medical Dictionary for Regulatory Activities
(MedDRA) version 13.0, and severity was noted. Vital
signs (i.e., blood pressure, heart rate, and respiratory rate)
were measured at baseline and again at study end or at
the time of rescue medication administration (if applic-
able). No laboratory evaluations were performed.
Study end points
There were 2 coprimary end points: (1) mean time-
weighted sum of PRR and Pain Intensity Difference (PID)
scores from 0 through 3 hours (SPRID 0–3) for IBUNa ver-
sus placebo and (2) time to MPR for IBUNa versus IBUMot.
The primary hypothesis in this superiority study was thata single oral dose of IBUNa would be more efficacious than
placebo in the treatment of ETTH. The coprimary hy-
pothesis was that IBUNa would have a faster onset of ac-
tion, as assessed by time to MPR, than IBUMot in the
treatment of ETTH.
Secondary efficacy end points included time to MPR
for the remaining comparisons and time to FPR (con-
firmed by MPR) for all pairwise comparisons. Other sec-
ondary assessments (all pairwise comparisons) included
PRR, PID, and sum of PRR and PID (PRID) scores at 1,
2, and 3 hours postdose. The following summary efficacy
scores were also compared over 2 and 3 hours postdose
for all nonprimary pairwise comparisons: sum of PID
scores (SPID 0–2 and 0–3), time-weighted sum of PRR
scores (TOTPAR 0–2 and 0–3), and SPRID 0–2 and
0–3. The cumulative proportions of subjects achieving
MPR and FPR were assessed at 0.5, 1, 2, and 3 hours
postdose, and the cumulative proportions achieving
complete relief were assessed at 1, 2, and 3 hours. Add-
itional secondary assessments included duration of pain
relief as measured by time to treatment failure (i.e., time
to rescue medication use or discontinuation due to lack
of efficacy) and cumulative proportion of treatment fail-
ures at 1, 2, and 3 hours. Safety end points included
frequency and severity of treatment-emergent AEs and
frequency of serious AEs.
Power calculation and sample size
An estimated sample size of 225 subjects (90 subjects in
each active treatment group and 45 in the placebo
group) was needed to provide at least 80% power at the
5% level of significance (2-sided) to allow detection of a
2.3-unit difference in SPRID 0–3 between IBUNa and
placebo and to detect a hazard ratio (HR) of 1.6 for
comparison of time to MPR between IBUNa and IBUMot.
Statistical analyses
Efficacy analyses were based on the intent-to-treat (ITT)
population, which included all randomized subjects who
received study drug and provided a baseline assessment.
The safety population consisted of all subjects who took
study medication.
PID, SPID, PRID, SPRID, PRR, and TOTPAR were an-
alyzed using analysis of variance (ANOVA), with treat-
ment, gender, and baseline pain severity terms included
in the model. Least-squares means from the ANOVA
model were used to compute 95% confidence intervals
(CIs) for each pairwise treatment difference. The distri-
bution of time to MPR, time to FPR (confirmed by time
to MPR to minimize placebo response), and time to
treatment failure were analyzed using the proportional
hazards regression model, with terms for treatment, gen-
der, and baseline pain severity in the model. The Cochran-
Mantel-Haenszel (CMH) test, controlling for gender and
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proportions of subjects with MPR, FPR, complete relief,
and treatment failure at each specified time point. In
addition to the prespecified statistical analysis, a post hoc
analysis evaluated time to event data (time to FPR and
MPR) using the Gehan-Wilcoxon test, which assigns
higher weights to earlier events. This is in contrast to the
proportional hazards regression of the CMH test, which
assigns equal weight to all events.
All statistical computations were performed using SAS
version 9.2 (SAS Institute, Cary, NC). Two-sided between-
group tests were conducted at the 5% level of significance.
For protection from type I error due to multiple end
points, the primary end points were tested sequentially.
For protection from type I error due to multiple compari-
sons, each pairwise comparison was eligible for signifi-
cance only if the corresponding overall treatment effect
among the 3 groups was also significant.
The authors had full access to all the data in the study
and take responsibility for the integrity of the data and
the accuracy of the data analysis.
Results
Subject disposition and baseline characteristics
Of 243 screened subjects, 226 were randomized to IBUNa
(n = 91), IBUMot (n = 89), and placebo (n = 46). All of the
randomized participants received study medications andFigure 1 Subject disposition. IBUMot, Motrin
®; IBUNa, ibuprofen sodium dicompleted the study (i.e., there were no early with-
drawals); thus, all 226 randomized participants constituted
the ITT and safety populations (Figure 1). Most subjects
were women, nearly all were Caucasian, and the average
subject age was 42.8 years (range: 18–65). Treatment




SPRID 0–3 The mean SPRID 0–3 scores were 9.6, 9.8,
and 3.5 for IBUNa, IBUMot, and placebo, respectively
(Figure 2). The SPRID 0–3 score was statistically signifi-
cantly better for IBUNa versus placebo (treatment differ-
ence 6.11; 95% CI 4.49–7.73; P < .001). Likewise, IBUMot
also had a SPRID 0–3 score that was statistically signifi-
cantly better than placebo (treatment difference 6.27;
95% CI 4.65–7.89; P < .001). The SPRID 0–3 scores for
IBUNa and IBUMot were not significantly different from
each other (treatment difference −0.16; 95% CI −1.49–
1.17; P = .812). Thus, as expected, both active treat-
ments provided superior pain relief compared with
placebo.
Time to MPR Median time to MPR was significantly
faster for IBUNa (40.6 minutes; HR 4.38; 95% CI 2.69–
7.14; P < .001) and for IBUMot (48.5 minutes; HR 3.64;hydrate; ITT, intent-to-treat.









Male 16 (34.8) 31 (34.1) 30 (33.7)
Female 30 (65.2) 60 (65.9) 59 (66.3)
Race, n (%)
White/Caucasian 46 (100.0) 88 (96.7) 86 (96.6)
Black 0 3 (3.3) 3 (3.4)
Ethnicity, n (%)
Non-Hispanic 46 (100.0) 91 (100.0) 89 (100.0)
Age, mean (SD), y 39.9 (15.2) 42.3 (14.3) 44.8 (13.5)
Time with recurrent headaches,
mean (SD), y
12.3 (9.0) 12.8 (8.7) 13.2 (7.6)
Tension headache frequency,
past 6 months, mean (SD)
5.5 (1.7) 5.9 (2.3) 6.0 (2.2)
Pain VAS, mean (SD), mm 82.1 (9.0) 82.1 (8.9) 81.9 (8.4)
Categorical pain severity, n (%)
Moderately severe 36 (78.3) 73 (80.2) 70 (78.7)
Severe 10 (21.7) 18 (19.8) 19 (21.3)
IBUMot, Motrin
®; IBUNa, ibuprofen sodium; SD, standard deviation; VAS, visual
analog scale.
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(>180 minutes). The shorter time to MPR noted for
IBUNa compared with IBUMot was not statistically sig-
nificant using the prespecified analysis (HR 1.20; 95%
CI 0.88–1.65; P = .253; Figure 3). However, using a post
hoc analysis (Gehan-Wilcoxon test), which assigns
higher weights to earlier events, MPR was reached
significantly faster with IBUNa compared with IBUMot
(P = .022).Figure 2 Two- and 3-hour summary efficacy measures. *P≤ .001 vs placeb
SPID, sum of pain intensity difference scores; SPRID, time-weighted sum of Pain
sum of Pain Relief Rating scores; 0–3, from time 0 to 3 hours after study adminSecondary efficacy
Time to FPR Median time to FPR was 36.9 minutes for
IBUNa, 43.6 minutes for IBUMot, and >180 minutes for
placebo (Figure 4). Compared with placebo, both IBUNa
(HR 4.68; 95% CI 2.87–7.64; P < .001) and IBUMot (HR
3.88; 95% CI 2.38–6.34; P < .001) had significantly faster
times to FPR. Time to FPR was not significantly different
between IBUNa and IBUMot using the prespecified ana-
lysis (HR 1.21; 95% CI 0.88–1.66; P = .247); however, in
the post hoc analysis (Gehan-Wilcoxon test), IBUNa pro-
vided a significantly faster time to FPR compared with
IBUMot (P = .018).PRID
The PRID (sum of PRR and PID) scores were signifi-
cantly better for both IBUNa and IBUMot versus placebo
at 1, 2, and 3 hours (Figure 5; P < .001 for all compari-
sons), providing further evidence that both active treat-
ments provided significant pain relief and reductions in
pain intensity. IBUNa and IBUMot were not significantly
different from each other with regard to PRR, PID, and
PRID scores at any time point.SPRID 0–2 and other summary efficacy scores
Results for the other summary efficacy end points, con-
sisting of 0–2- and 0–3-hour SPID, TOTPAR, and
SPRID, were consistent with those for SPRID 0–3
(i.e., IBUNa and IBUMot were significantly better than
placebo [P < .001] for each measure but not significantly
different from each other) (Figure 2). Results of primary
and secondary efficacy end points stratified by baseline
pain status (moderately severe and severe) were generally
consistent with those observed in the overall ITT popula-
tion; therefore, these subgroup analyses are not shown.o; IBUMot, Motrin
®; IBUNa, ibuprofen sodium dihydrate; SE, standard error;
Relief Rating and pain intensity difference scores; TOTPAR, time-weighted
istration; 0–2, from time 0 to 2 hours after study administration.
Figure 3 Time to meaningful pain relief (hour 0–1). *P < .001 vs
placebo; IBUMot, Motrin
®; IBUNa, ibuprofen sodium dihydrate; MPR,
meaningful pain relief.
Figure 5 Sum of pain relief rating and pain intensity difference
(PRID) scores over time. *IBUNa and IBUMot both P < .001 vs placebo;
IBUMot, Motrin
®; IBUNa, ibuprofen sodium dihydrate.
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Cumulative proportions of subjects achieving FPR or
MPR by 0.5, 1, 2, and 3 hours are shown in Table 2. At
30 minutes postdose, 18.7% of the IBUNa-treated group,
7.9% of the IBUMot-treated group, and 0 subjects in the
placebo group reported FPR. At this time point, signifi-
cantly more subjects treated with IBUNa experienced
FPR compared with either placebo (treatment difference
18.58, 95% CI 10.43–26.73; P = .002) or IBUMot (treat-
ment difference 10.91; 95% CI 0.98–20.83; P = .033). The
treatment difference for FPR at 30 minutes between
IBUMot and placebo (treatment difference 7.80; 95% CI
2.14–13.46; P = .055) trended towards statistical signifi-
cance. Meaningful pain relief was reported by 12.1% of
the IBUNa group, 4.5% of the IBUMot group, and 0 sub-
jects in the placebo group by 30 minutes postdose. ThisFigure 4 Time to first perceptible pain relief (hour 0–1). *P < .001
vs placebo; FPR, first perceptible relief; IBUMot, Motrin
®; IBUNa, ibuprofen
sodium dihydrate.difference in MPR was significant for IBUNa versus pla-
cebo (treatment difference 12.02; 95% CI 5.27–18.77;
P = .015) but not for IBUMot vs placebo (treatment dif-
ference 4.50; 95% CI 0.13–8.88; P = .146); the difference
in MPR for IBUNa versus IBUMot at 30 minutes was
borderline significant (treatment difference 7.62; 95%
CI: −0.38–15.63; P = .064).
By 1 hour, proportions of subjects attaining FPR and
MPR were significantly greater for both active treatment
groups versus placebo (P < .001). At hour 3 (end of
study), significantly more subjects in both active treat-
ment groups had achieved FPR, MPR, and complete re-
lief versus placebo (P < .001 for all comparisons).
Treatment failure
No subject took rescue medication or discontinued due
to lack of efficacy. Therefore, time to treatment failure
could not be assessed.
Safety evaluation
Both formulations of IBU were well tolerated. There
were no treatment-emergent AEs, deaths, serious AEs,
or significant changes in vital signs reported during the
study.
Discussion
The novel IBU formulation described herein was devel-
oped as an immediate-release tablet formulation con-
taining 256 mg of IBUNa as the dihydrate salt. This
formulation provides 200 mg of IBU free acid, which is
the amount in currently marketed OTC IBU tablets in
the United States and many other countries. In this
study, as expected, both IBUNa and IBUMot provided sig-
nificantly better relief of ETTH than placebo across mul-
tiple efficacy end points and provided equivalent overall
pain relief. No AEs were reported in the study, and all
Table 2 Cumulative proportion of subjects achieving relief at 0.5, 1, 2, and 3 hours
Proportion of subjects achieving
end point, %
Treatment difference (95% CI) P valuea
IBUNa IBUMot Placebo IBUNa vs Placebo IBUNa vs IBUMot IBUMot vs Placebo
30 minutes
FPR 18.7 7.9 0 18.58 (10.43–26.73) P = .002 10.91 (0.98–20.83) P = .033 7.80 (2.14–13.46) P = .055
MPR 12.1 4.5 0 12.02 (5.27–18.77) P = .015 7.62 (−0.38–15.63) P = .064 4.50 (0.13–8.88) P = .146
1 hour
FPR 76.9 74.2 15.2 62.03 (48.65–75.41) P < .001 2.96 (−9.52–15.44) P = .642 59.44 (45.69–73.19) P < .001
MPR 71.4 65.2 13.0 58.58 (44.96–72.21) P < .001 6.40 (−7.27–20.07) P = .357 52.31 (38.20–66.41) P < .001
Complete relief 0 0 0 NA NA NA
2 hours
FPR 85.7 86.5 45.7 40.26 (23.85–56.68) P < .001 −0.72 (−10.89–9.45) P = .889 41.19 (24.78–57.59) P < .001
MPR 85.7 86.5 39.1 46.68 (30.43–62.93) P < .001 −0.72 (−10.89–9.45) P = .889 47.59 (31.35–63.83) P < .001
Complete relief 5.5 4.5 2.2 3.21 (−3.12–9.55) P = .389 0.98 (−5.45–7.41) P = .764 2.35 (−3.69–8.39) P = .490
3 hours
FPR 85.7 86.5 45.7 40.26 (23.85–56.68) P < .001 −0.72 (−10.89–9.45) P = .889 41.19 (24.78–57.59) P < .001
MPR 85.7 86.5 45.7 40.26 (23.85–56.68) P < .001 −0.72 (−10.89–9.45) P = .889 41.19 (24.78–57.59) P < .001
Complete relief 37.4 38.2 8.7 28.71 (15.72–41.70) P < .001 −0.93 (−15.22–13.36) P = .898 29.37 (16.19–42.56) P < .001
aTreatment difference (first treatment – second treatment) and its associated CI were calculated based on the Cochran-Mantel-Haenszel (CMH) adjusted proportions
and the corresponding standard errors; P values from the CMH test, controlling for baseline Pain Severity Rating and gender. CI, confidence interval; FPR, first perceptible
relief; IBUMot, Motrin
®; IBUNa, ibuprofen sodium; MPR, meaningful pain relief; NA, not applicable. Statistically significant differences are indicated by bold type.
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in this ETTH study mirrors that of a previously pub-
lished study, which showed that solubilized IBU pro-
vided significantly faster, and superior, pain relief than
acetaminophen tablets (P ≤ .02) [19].
According to the primary protocol-specified analysis,
IBUNa did not provide statistically significantly faster re-
lief of ETTH than IBUMot. However, IBUNa was numer-
ically faster than IBUMot by 6.7 minutes for onset of FPR
and by 7.9 minutes for onset of MPR. In a post hoc ana-
lysis using the Gehan-Wilcoxon test, which assigns higher
weights to earlier events, these differences were statisti-
cally significant. The post hoc analysis was performed be-
cause results of earlier studies using the third molar
extraction model of dental pain showed that IBUNa pro-
vides a more rapid onset of analgesic effect compared with
other standard IBU products [14,15,17] and because, in
the current study, the Kaplan-Meier graphs and results for
percentage of subjects reporting FPR confirmed by MPR
showed trends and significant differences, respectively, fa-
voring IBUNa over IBUMot at earlier time points. Results
from the analyses of cumulative proportions of subjects
achieving relief also suggest an advantage for IBUNa dur-
ing the first 30 minutes postdose: more subjects in the
IBUNa group attained confirmed FPR within 30 minutes
compared with IBUMot, and the proportion with MPR was
significantly different from placebo starting at 30 minutes
for IBUNa whereas the difference versus placebo did not
become significant until 1 hour postdose for IBUMot.Prior studies evaluating other formulations of IBUNa in
postoperative dental pain models have demonstrated
that IBUNa has a faster onset of analgesia relative to
standard IBU. Schleier et al. [14] randomized 396 subjects
who had undergone third molar extraction to IBUNa (2 ×
256 mg, equivalent to 400 mg standard IBU) or standard
IBU (2 × 200 mg). Onset of pain relief occurred earlier
and relief increased faster in the IBUNa group, and the me-
dian time to substantial pain relief was 42 minutes with
IBUNa versus 56 minutes with standard IBU. Similarly,
Norholt et al. [15] randomized 144 subjects to receive a
single dose of either IBUNa or standard IBU following
third molar extraction on the first surgical day and then
were crossed over to the opposite treatment following
removal of a second third molar on the second surgical
day. In this study, IBUNa produced onset of pain relief
6 minutes faster (P = .004) and provided substantial relief
within 30 minutes for twice as many subjects (11% versus
5%) as did standard IBU.
The formulation of IBUNa used in the current study
was also previously assessed in the third molar extrac-
tion model of dental pain. Brain et al. [17] randomized
316 subjects to receive IBUNa (2 × 256 mg), 2 different
formulations of standard IBU (2 × 200 mg), or placebo,
and monitored subjects for 8 hours postdose. Time to
MPR, 1 of 2 coprimary end points, was significantly
(P < .001) faster with IBUNa (median 42.4 minutes) than
with placebo (>8 hours), pooled standard IBU (55.3 mi-
nutes) or IBUMot (60.7 minutes). As expected, IBUNa
Packman et al. Journal of Pharmaceutical Health Care and Sciences  (2015) 1:13 Page 8 of 9was associated with a SPRID 0–8 score that was signifi-
cantly better than placebo (P < .001) and comparable to
standard IBU [17]. The discrepancy between results seen
in the dental pain model and the current study in ETTH
could be due to a difference in model sensitivity. The
third molar extraction model of dental pain is the most
widely used model for assessing acute analgesia and has
well established model sensitivity and reproducibility
[24]. The surgical methodology is standardized and the
resultant levels of postsurgical pain are probably much
higher and less variable than those in tension headache,
which is a naturalistic as opposed to an induced, post-
surgical pain model.
The current study extends the findings of rapid onset
of analgesic efficacy with IBUNa observed in dental pain
studies to ETTH. Rapid onset of analgesia is a highly de-
sirable attribute in the treatment of ETTH, the most
common type of primary headache. ETTH affects up to
three-quarters of the population at some point in their
lives [1], causing suffering and contributing to office
visits, hospital admissions, and absenteeism [25]. Safe,
effective, and fast-acting treatments may help reduce
ETTH-related disability and improve quality of life.
There are potential limitations of this study. The
study population was very homogeneous, with 97%
white/Caucasian subjects, which may limit extrapola-
tion of results to the general population. However, the
authors are not aware of any racial differences in the
response to IBU or other NSAIDs for the treatment of
tension headache. Another possible limitation is the ex-
ternal validity in relation to other types of pain. How-
ever, OTC IBU and other NSAIDs are efficacious in
both the treatment of tension headache and other types
of acute pain, and this particular formulation of IBU
with sodium has also been demonstrated to be effica-
cious and fast-acting in the treatment of postsurgical
dental pain [17].Conclusions
In conclusion, this single-dose study indicates that a
novel IBUNa tablet formulation provides fast-acting and
efficacious relief of ETTH. Both IBUNa and standard
IBU were significantly better than placebo for all efficacy
parameters studied, and there were no AEs in any treat-
ment group. Median FPR was nearly 7 minutes faster
and median MPR was approximately 8 minutes faster
with IBUNa than standard IBU tablets. Although these
differences were not statistically significant using the
prespecified statistical analyses, they were statistically
significant in post hoc analyses using a methodology that
assigns higher weights to earlier events. In addition, sig-
nificantly more subjects achieved FPR within 30 minutes
with IBUNa versus standard IBU. Thus, this formulationof IBUNa is as safe and effective as standard IBU and
provides fast-acting relief of ETTH.
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